Polymer based Drug Delivery Systems- benchtop to Bedside Transition
Loading...
Permanent Link
Author/Creator
Author/Creator ORCID
Date
2021-06-29
Type of Work
Department
Program
Citation of Original Publication
Ray, Priyanka; Polymer based Drug Delivery Systems- benchtop to Bedside Transition; Scientific and Research Community, 29 June, 2021; https://www.onlinescientificresearch.com/articles/polymer-based-drug-delivery-systems-benchtop-to-bedside-transition.pdf
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution 4.0 International (CC BY 4.0)
Attribution 4.0 International (CC BY 4.0)
Subjects
Abstract
Research in the field of polymers and polymeric materials has garnered immense attention in the past few decades due to the versatile functional and
structural capabilities of polymers which often can be manipulated for applications in the field of therapy and diagnosis for a host of diseases and disorders.
Polymer therapeutics comprises polymer-drug and polymer-protein conjugates as well as supramolecular systems used as drug delivery systems. Although the
pharmacological industry invests immensely in the design and discovery of novel drug molecules, small molecular drugs are often inefficient in targeting many
diseases like deep seated low vasculature tumours, metastasized cancers and various autoimmune diseases. Coupled with a rapid clearance rate, low solubility,
drug resistance and high off target toxicity these small molecular drugs often present modest benefits for a host of common diseases. In order to improve the
therapeutic index of pre-existing drugs and shortening the translation from preclinical validation to clinical approval, a vast area of drug delivery research focuses
on the improvement of drug carriers by various alterations. The major challenges currently faced by drug delivery systems include a low payload, transition
through the desmoplastic barrier for solid tumours and high hepatic and renal clearance. In order to address these issues numerous polymer–protein and
polymer-drug conjugates have been engineered and have reported to enhance the stability and pharmacokinetic properties of the active drugs. Highly toxic
anticancer drugs like doxorubicin, cis-platin and gemcitabine have successfully been coupled with high molecular weight polymers to formulate targeted drug
delivery agents, some of which have undergone successful clinical trials. Apart from PEGylated polymers, dendritic polymers and polyplexes with DNA or RNA
moieties have also been considered as candidates for improving the therapeutic index of various drugs. Ongoing efforts in the development of polymer-based
therapeutics are promising and open new horizons for personalized medicine for effective cure of various life-threatening diseases.